General MedicationsINTRAVENOUSStandard
BAVENCIO
AVELUMAB
Standard Dose
20MG/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview BAVENCIO is listed in Drugs@FDA under application 761078 (BLA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient AVELUMAB Form and strength INJECTABLE;INTRAVENOUS - 20MG/ML Sponsor EMD SERONO INC Submission history Latest submission status date: 2017-05-09 00:00:00.
Structured Monograph
Clinical summary
Approval overview BAVENCIO is listed in Drugs@FDA under application 761078 (BLA). Review priority: PRIORITY Marketing status: Prescription Active ingredient AVELUMAB Form and strength INJECTABLE;INTRAVENOUS - 20MG/ML Sponsor EMD SERONO INC Submission history Latest submission status date: 2017-05-09 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.